6UI.F ARECOR THERAPEUTICS -01

Healthcare Biotechnology Frankfurt Exchange
0.8100 EUR
Close of Nov 11, 2026
0.5050 0.9350
Market cap
EUR 36.7M
P/E
81.0x
P/B
8.32x
ROE
10.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6UI.F undervalued?

Graham number

The Graham number of ARECOR THERAPEUTICS -01 cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ARECOR THERAPEUTICS -01 fundamental analysis

No fundamental analysis for ARECOR THERAPEUTICS -01 yet.

ARECOR THERAPEUTICS -01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ARECOR THERAPEUTICS -01

Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics p…

Full company profile